Growth inhibition and chemo‑radiosensitization of esophageal squamous cell carcinoma by survivin‑shRNA lentivirus transfection

Zhou,Changlin; Zhang,Lin; Xu,Peng

doi:10.3892/ol.2018.9280

Growth inhibition and chemo‑radiosensitization of esophageal squamous cell carcinoma by survivin‑shRNA lentivirus transfection

Authors:
- Changlin Zhou
- Lin Zhang
- Peng Xu
View Affiliations

Affiliations: Department of Oncology, Jining First People's Hospital, Jining, Shandong 272011, P.R. China, Department of Thoracic Surgery, Ji'nan Central Hospital Affiliated to Shandong University, Ji'nan, Shandong 250013, P.R. China
Published online on: August 8, 2018 https://doi.org/10.3892/ol.2018.9280
Pages: 4813-4820
Copyright: © Zhou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Esophageal cancer is one of the most common types of cancer worldwide, and it has a poor prognosis. Chemo‑radiotherapy resistance and cancer relapse are among the most difficult issues in its treatment. Identifying the underlying molecular mechanisms is critical for developing novel therapies. Survivin has been previously suggested to be overexpressed in esophageal cancer cells. The present study identified that down‑regulation of survivin sensitized esophageal cancer cells to chemo‑radiotherapy. Consistent with previous studies, the present study indicated that survivin was overexpressed in 4 esophageal squamous carcinoma cell lines. Short hairpin RNA delivered by lentivirus successfully knocked down survivin in these cancer cell lines. Consequently, down‑regulation of survivin impaired their colony‑forming, migratory and invasive capabilities, while the overexpression of survivin in normal human esophagus epithelial cells improved their resistance to cisplatin, paclitaxel and radiation. Survivin knockdown induced apoptosis in esophageal cancer KYSE‑150 and ECA‑109 cell lines when exposed to the aforementioned chemo‑radiotherapy treatments. These results indicate that survivin expression sustains growth in esophageal cancer cells, and confers resistance to chemo‑radiotherapy. Targeted survivin ablation may be a promising strategy against esophageal tumor relapse and chemo‑radioresistance.

View Figures

View References

1	Zhang Y: Epidemiology of esophageal cancer. World J Gastroenterol. 19:5598–5606. 2013. View Article : Google Scholar : PubMed/NCBI
2	Napier KJ, Scheerer M and Misra S: Esophageal cancer: A Review of epidemiology, pathogenesis, staging workup and treatment modalities. World J Gastrointest Oncol. 6:112–120. 2014. View Article : Google Scholar : PubMed/NCBI
3	Lin Y, Totsuka Y, He Y, Kikuchi S, Qiao Y, Ueda J, Wei W, Inoue M and Tanaka H: Epidemiology of esophageal cancer in Japan and China. J Epidemiol. 23:233–242. 2013. View Article : Google Scholar : PubMed/NCBI
4	Hiripi E, Jansen L, Gondos A, Hiripi E, Jansen L, Gondos A, Emrich K, Holleczek B, Katalinic A, Luttmann S, et al: Survival of stomach and esophagus cancer patients in Germany in the early 21st century. Acta Oncol. 51:906–914. 2012. View Article : Google Scholar : PubMed/NCBI
5	van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, Richel DJ, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, et al: Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 366:2074–2084. 2012. View Article : Google Scholar : PubMed/NCBI
6	Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J and Simes J: Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: A meta-analysis. Lancet Oncol. 8:226–234. 2007. View Article : Google Scholar : PubMed/NCBI
7	Ando N, Kato H, Igaki H, Shinoda M, Ozawa S, Shimizu H, Nakamura T, Yabusaki H, Aoyama N, Kurita A, et al: A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 19:68–74. 2012. View Article : Google Scholar : PubMed/NCBI
8	Sgourakis G, Gockel I, Karaliotas C, Moehler M, Schimanski CC, Schmidberger H and Junginger T: Survival after chemotherapy and/or radiotherapy versus self-expanding metal stent insertion in the setting of inoperable esophageal cancer: A case-control study. BMC Cancer. 12:702012. View Article : Google Scholar : PubMed/NCBI
9	Liao Z, Cox JD and Komaki R: Radiochemotherapy of esophageal cancer. J Thorac Oncol. 2:553–568. 2007. View Article : Google Scholar : PubMed/NCBI
10	Smit JK, Faber H, Niemantsverdriet M, Baanstra M, Bussink J, Hollema H, van Os RP, Plukker JT and Coppes RP: Prediction of response to radiotherapy in the treatment of esophageal cancer using stem cell markers. Radiother Oncol. 107:434–441. 2013. View Article : Google Scholar : PubMed/NCBI
11	Hummel R, Sie C, Watson DI, Wang T, Ansar A, Michael MZ, van der Hoek M, Haier J and Hussey DJ: MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines. World J Gastroenterol. 20:14904–14912. 2014. View Article : Google Scholar : PubMed/NCBI
12	Ferrario A, Rucker N, Wong S, Luna M and Gomer CJ: Survivin, a member of the inhibitor of apoptosis family, is induced by photodynamic therapy and is a target for improving treatment response. Cancer Res. 67:4989–4995. 2007. View Article : Google Scholar : PubMed/NCBI
13	Eckelman BP, Salvesen GS and Scott FL: Human inhibitor of apoptosis proteins: Why XIAP is the black sheep of the family. EMBO Rep. 7:988–994. 2006. View Article : Google Scholar : PubMed/NCBI
14	Suzuki Y, Nakabayashi Y and Takahashi R: Ubiquitin-protein ligase activity of X-linked inhibitor of apoptosis protein promotes proteasomal degradation of caspase-3 and enhances its anti-apoptotic effect in Fas-induced cell death. Proc Natl Acad Sci USA. 98:8662–8667. 2001. View Article : Google Scholar : PubMed/NCBI
15	Rodel F, Sprenger T, Kaina B, Liersch T, Rödel C, Fulda S and Hehlgans S: Survivin as a prognostic/predictive marker and molecular target in cancer therapy. Curr Med Chem. 19:3679–3688. 2012. View Article : Google Scholar : PubMed/NCBI
16	Mobahat M, Narendran A and Riabowol K: Survivin as a preferential target for cancer therapy. Int J Mol Sci. 15:2494–2516. 2014. View Article : Google Scholar : PubMed/NCBI
17	Kato J, Kuwabara Y, Mitani M, Shinoda N, Sato A, Toyama T, Mitsui A, Nishiwaki T, Moriyama S, Kudo J and Fujii Y: Expression of survivin in esophageal cancer: Correlation with the prognosis and response to chemotherapy. Int J Cancer. 95:92–95. 2001. View Article : Google Scholar : PubMed/NCBI
18	Xia H, Chen S, Huang H and Ma H: Survivin over-expression is correlated with a poor prognosis in esophageal cancer patients. Clin Chim Acta. 446:82–85. 2015. View Article : Google Scholar : PubMed/NCBI
19	Rosato A, Pivetta M, Parenti A, Iaderosa GA, Zoso A, Milan G, Mandruzzato S, Del Bianco P, Ruol A, Zaninotto G and Zanovello P: Survivin in esophageal cancer: An accurate prognostic marker for squamous cell carcinoma but not adenocarcinoma. Int J Cancer. 119:1717–1722. 2006. View Article : Google Scholar : PubMed/NCBI
20	Wang Y, Zhu H, Quan L, Zhou C, Bai J, Zhang G, Zhan Q and Xu N: Downregulation of survivin by RNAi inhibits the growth of esophageal carcinoma cells. Cancer Biol Ther. 4:974–978. 2005. View Article : Google Scholar : PubMed/NCBI
21	Zeng W, Li H, Chen Y, Lv H, Liu L, Ran J, Sun X, Bieerkehazhi S, Liu Y, Li X, et al: Survivin activates NF-κB p65 via the IKKβ promoter in esophageal squamous cell carcinoma. Mol Med Rep. 13:1869–1880. 2016. View Article : Google Scholar : PubMed/NCBI
22	Moffat J, Grueneberg DA, Yang X, Kim SY, Kloepfer AM, Hinkle G, Piqani B, Eisenhaure TM, Luo B, Grenier JK, et al: A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell. 124:1283–1298. 2006. View Article : Google Scholar : PubMed/NCBI
23	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
24	Liang CC, Park AY and Guan JL: In vitro scratch assay: A convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc. 2:329–333. 2007. View Article : Google Scholar : PubMed/NCBI
25	Khan Z, Khan AA, Prasad GB, Khan N, Tiwari RP and Bisen PS: Growth inhibition and chemo-radiosensitization of head and neck squamous cell carcinoma (HNSCC) by survivin-siRNA lentivirus. Radiother Oncol. 118:359–368. 2016. View Article : Google Scholar : PubMed/NCBI
26	Plescia J, Salz W, Xia F, Pennati M, Zaffaroni N, Daidone MG, Meli M, Dohi T, Fortugno P, Nefedova Y, et al: Rational design of shepherdin, a novel anticancer agent. Cancer Cell. 7:457–468. 2005. View Article : Google Scholar : PubMed/NCBI
27	Minoda M, Kawamoto T, Ueha T, Kamata E, Morishita M, Harada R, Toda M, Onishi Y, Hara H, Kurosaka M and Akisue T: Antitumor effect of YM155, a novel small-molecule survivin suppressant, via mitochondrial apoptosis in human MFH/UPS. Int J Oncol. 47:891–899. 2015. View Article : Google Scholar : PubMed/NCBI
28	Nakahara T, Kita A, Yamanaka K, Mori M, Amino N, Takeuchi M, Tominaga F, Hatakeyama S, Kinoyama I, Matsuhisa A, et al: YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res. 67:8014–8021. 2007. View Article : Google Scholar : PubMed/NCBI
29	Kelly RJ, Thomas A, Rajan A, Chun G, Lopez-Chavez A, Szabo E, Spencer S, Carter CA, Guha U, Khozin S, et al: A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer. Ann Oncol. 24:2601–2606. 2013. View Article : Google Scholar : PubMed/NCBI
30	Clemens MR, Gladkov OA, Gartner E, Vladimirov V, Crown J, Steinberg J, Jie F and Keating A: Phase II, multicenter, open-label, randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancer. Breast Cancer Res Treat. 149:171–179. 2015. View Article : Google Scholar : PubMed/NCBI
31	Ma WH, Liu YC, Xue ML, Zheng Z and Ge YL: Downregulation of survivin expression exerts antitumoral effects on mouse breast cancer cells in vitro and in vivo. Oncol Lett. 11:159–167. 2016. View Article : Google Scholar : PubMed/NCBI
32	Wang H and Ye YF: Effect of survivin siRNA on biological behaviour of breast cancer MCF7 cells. Asian Pac J Trop Med. 8:225–228. 2015. View Article : Google Scholar : PubMed/NCBI
33	Kogo R, How C, Chaudary N, Bruce J, Shi W, Hill RP, Zahedi P, Yip KW and Liu FF: The microRNA-218~Survivin axis regulates migration, invasion, and lymph node metastasis in cervical cancer. Oncotarget. 6:1090–1100. 2015. View Article : Google Scholar : PubMed/NCBI
34	Wang J, Li Z, Lin Z, Zhao B, Wang Y, Peng R, Wang M, Lu C, Shi G and Shen Y: 17-DMCHAG, a new geldanamycin derivative, inhibits prostate cancer cells through Hsp90 inhibition and survivin downregulation. Cancer Lett. 362:83–96. 2015. View Article : Google Scholar : PubMed/NCBI
35	Carew JS, Espitia CM, Zhao W, Mita MM, Mita AC and Nawrocki ST: Targeting survivin inhibits renal cell carcinoma progression and enhances the activity of temsirolimus. Mol Cancer Ther. 14:1404–1413. 2015. View Article : Google Scholar : PubMed/NCBI
36	Tsubaki M, Takeda T, Ogawa N, Sakamoto K, Shimaoka H, Fujita A, Itoh T, Imano M, Ishizaka T, Satou T and Nishida S: Overexpression of survivin via activation of ERK1/2, Akt, and NF-κB plays a central role in vincristine resistance in multiple myeloma cells. Leuk Res. 39:445–452. 2015. View Article : Google Scholar : PubMed/NCBI
37	Shen X, Zheng JY, Shi H, Zhang Z and Wang WZ: Survivin knockdown enhances gastric cancer cell sensitivity to radiation and chemotherapy in vitro and in nude mice. Am J Med Sci. 344:52–58. 2012. View Article : Google Scholar : PubMed/NCBI
38	Morrison DJ, Hogan LE, Condos G, Bhatla T, Germino N, Moskowitz NP, Lee L, Bhojwani D, Horton TM, Belitskaya-Levy I, et al: Endogenous knockdown of survivin improves chemotherapeutic response in ALL models. Leukemia. 26:271–279. 2012. View Article : Google Scholar : PubMed/NCBI
39	Kunze D, Erdmann K, Froehner M, Wirth MP and Fuessel S: Enhanced inhibition of bladder cancer cell growth by simultaneous knockdown of antiapoptotic Bcl-xL and survivin in combination with chemotherapy. Int J Mol Sci. 14:12297–12312. 2013. View Article : Google Scholar : PubMed/NCBI
40	Cui M, Au JL, Wientjes MG, O'Donnell MA, Loughlin KR and Lu Z: Intravenous siRNA silencing of survivin enhances activity of mitomycin C in human bladder RT4 ×enografts. J Urol. 194:230–237. 2015. View Article : Google Scholar : PubMed/NCBI
41	Faversani A, Vaira V, Moro GP, Tosi D, Lopergolo A, Schultz DC, Rivadeneira D, Altieri DC and Bosari S: Survivin family proteins as novel molecular determinants of doxorubicin resistance in organotypic human breast tumors. Breast Cancer Res. 16:R552014. View Article : Google Scholar : PubMed/NCBI